Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

NCT02513459 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02513459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02513459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
September 16, 2015
Completion date
June 19, 2019
Enrollment
65 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease